Herceptin Approved In Two New Regimens
This article was originally published in The Pink Sheet Daily
Carboplatin substitutes for anthracyclines to reduce cardiac risk.
You may also be interested in...
Trastuzumab is cleared for adjuvant treatment in HER2-positive node-positive and node-negative breast cancer as a single agent or combined with hormonal therapy.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.